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Introduction & objectives
Osteoporosis is defined as a progressive systemic disease
characterised by low bone mass and architectural dete-
rioration of bone tissue, with consequent increased bone
fragility. The disease is predominately a disease of postme-
nopausal women and those prescribed long-term oral cor-
ticosteroids, but may occur in all populations and ages. A
large number of patients are treated for osteoporosis in
Ireland and adherence is a major issue in it’s management.
Poor adherence to osteoporosis treatment has been well
documented and is a widely recognised problem, resulting
in a huge burden on patients and the healthcare system.
In particular, poor adherence results in an increased num-
ber of fractures and consequent pain and disability. The
authors noted that patients frequently stated they did not
wish to have their osteoporosis medication dispensed. In
practice, a number of factors affect adherence to medica-
tion and there are numerous ways it can be improved. The
objectives of this study were to ascertain the extent of fail-
ures to refill prescriptions for osteoporosis medications in
the community setting, and to make recommendations.
Methods
An extensive literature review was carried out to obtain an
overview of the topic under research. This was also used
for comparative purposes. A retrospective review of pre-
scription records of 200 patients (N=200 F=168 M=32)
who were prescribed osteoporosis medications from Janu-
ary 2011- June 2011 was completed. Data from 17 phar-
macies with mixed demographics in the Munster and
south Leinster regions was used. The details recorded
were the dates of refill, the number of refills per six
months, number of concurrent medications including
other osteoporosis treatments, gender, age and whether
the patient paid for the medication or obtained it free of
charge. Adherence was classified using the medication
possession ratio (MPR).
Results & conclusions
There are a large and increasing number of osteoporosis
medications on the market in Ireland. As described in
the literature, adherence was sub-optimal. The adherence
to oral calcium and vitamin D supplements was 48%,
bisphosphonates 69%, Selective Oestrogen Receptor
Modulator (SERM) 84%, Dual Action Bone Agent
(DABA) Strontium 81%. There were significant variations
in adherence between the different classes of drugs and
variations within the same class. This varied with patient
demographics.
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